YIBAI PHARMACEUTICAL(SH:600594)2025-01-17 09:05Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -342 million and -285 million RMB, indicating a loss compared to the previous year[3]. - The projected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to be between -348 million and -290 million RMB[4]. - In 2023, the total profit was 132.32 million RMB, with a net profit attributable to shareholders of the parent company of 103.40 million RMB[6]. - The earnings per share for 2023 was 0.131 RMB[6]. Reasons for Expected Loss - The main reason for the expected loss is the halt in production and sales of the main product, Aidi injection, leading to a revenue decline of approximately 480 million RMB[7]. - Additionally, the price reduction of products such as injection-grade lobaplatin and ginkgo biloba injection resulted in a revenue decrease of about 190 million RMB[7]. Performance Forecast Validity - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant[8]. - The company assures that there are no significant uncertainties affecting the accuracy of this performance forecast[8]. - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report[9]. Announcement Details - The announcement was made by the board of directors on January 18, 2025[11].